This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies
NCT04689308
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
57
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed/Refractory B-cell Malignancies
Interventions
DRUG:
MH048
Sponsor
Minghui Pharmaceutical (Shanghai) LTD